Why insider trading matters?

What separates FormWhispers.com from others is that we created it to meet our own needs and we use it everyday to make better investment decisions. We will keep improving it to serve us better and to serve you better.

- Founders of FormWhispers.com
Aimmune Therapeutics, Inc. (AIMT)
Sector: Healthcare; Industry: Biotechnology

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2018-01-16 ADELMAN DANIEL C MD Chief Medical Officer Sell 36,717 $40.00 $1,468,680 Yes
2018-01-04 Sheehy Douglas T. See Remarks Sell 1,648 $37.33 $61,520 Yes
2018-01-02 Rozenman Mary M. See Remarks Sell 6,591 $37.11 $244,590 Yes
2018-01-02 Barrowcliffe Susan E. General Manager, Europe Sell 75,000 $37.14 $2,785,190 Yes
2017-12-27 ADELMAN DANIEL C MD Chief Medical Officer Sell 3,283 $40.00 $131,320 Yes
2017-12-26 Rozenman Mary M. See Remarks Sell 75,010 $38.88 $2,916,086 Yes
2017-12-26 Sheehy Douglas T. See Remarks Sell 1,875 $39.44 $73,950 Yes
2017-12-04 Sheehy Douglas T. See Remarks Sell 1,906 $38.66 $73,686 Yes
2017-11-30 Sheehy Douglas T. See Remarks Sell 3,750 $37.00 $138,750 Yes
2017-11-09 Sheehy Douglas T. See Remarks Sell 1,905 $33.00 $62,865 Yes
2017-10-23 DILLY STEPHEN GEORGE See Remarks Sell 100,000 $33.55 $3,354,538 No
2017-10-23 ADELMAN DANIEL C MD Chief Medical Officer Sell 10,000 $34.06 $340,610 Yes
2017-10-23 Sheehy Douglas T. See Remarks Sell 47,425 $34.44 $1,633,514 Yes
2017-10-16 DILLY STEPHEN GEORGE President and CEO Sell 1,154 $26.24 $30,279 No
2017-10-06 DILLY STEPHEN GEORGE President and CEO Sell 98,846 $26.24 $2,593,317 No
2017-09-25 ADELMAN DANIEL C MD Chief Medical Officer Sell 10,000 $25.00 $250,000 Yes
2017-09-25 DILLY STEPHEN GEORGE President and CEO Sell 100,000 $25.01 $2,500,790 No
2017-09-25 Barrowcliffe Susan E. General Manager, Europe Sell 20,000 $25.00 $500,000 Yes
2017-09-07 Rozenman Mary M. See Remarks Sell 30,000 $22.50 $675,000 Yes
2017-09-06 Barrowcliffe Susan E. General Manager, Europe Sell 18,390 $22.00 $404,615 Yes
2017-07-27 Barrowcliffe Susan E. General Manager, Europe Sell 500 $22.00 $11,000 Yes
2017-07-26 DILLY STEPHEN GEORGE President and CEO Sell 50,000 $21.46 $1,073,110 No
2017-07-25 Barrowcliffe Susan E. General Manager, Europe Sell 6,110 $22.00 $134,420 Yes
2017-07-21 Sheehy Douglas T. See Remarks Sell 7,460 $21.66 $161,558 No
2017-07-17 Rozenman Mary M. See Remarks Sell 14,940 $21.44 $320,247 Yes
2017-07-05 Rozenman Mary M. See Remarks Sell 45,060 $20.85 $939,390 Yes
2017-07-03 Barrowcliffe Susan E. General Manager, Europe Sell 15,000 $20.26 $303,910 Yes
2017-06-23 DILLY STEPHEN GEORGE President and CEO Sell 49,400 $20.21 $998,591 No
2017-05-12 BJERKHOLT ERIC Chief Financial Officer Buy 5,000 $19.84 $99,210 No
2017-05-10 DILLY STEPHEN GEORGE See Remarks Sell 600 $20.15 $12,090 No

Insider Smart

Ovintiv Inc (OVV) - Insiders of OVV have been HEAVILY accumulating shares in March with a sub-$3 cost. And the stock is now $11. An awesome 400% gain can't be missed if you found it was heavily accumulated earlier.

Insider Smart

Enphase Energy, Inc (ENPH) - ENPH was $10+ in 15Q1 then dropped to $2 and eventually went under $1. From 15Q4 to 17Q4 it built a 2-year-long base then BOOM! Stock went as high as $70 and likely will make a new high. Catch one or two moves like this you can retire early. One hint before the big move was that CEO and CFO were constantly accumulating, this kind of information is priceless.